P3 Health Partners Inc. — Form 10-Q Summary
Period: The filing covers the quarter and nine months ended September 30, 2022, and was filed November 14, 2022. The request metadata says 2021 Q3, but the supplied filing is for 2022 Q3. P3 provides population-health management, primarily under at-risk Medicare Advantage capitation contracts.
Financial performance and position
| Metric | Q3 2022 | Nine months 2022 |
|---|---|---|
| Revenue | $248.3 million | $791.3 million |
| Operating loss | $60.0 million | $1,024.4 million |
| Net loss | $65.3 million | $1,029.2 million |
| Net loss attributable to controlling interests | $11.2 million | $176.1 million |
| Operating cash flow | Not stated for the quarter | $(94.1) million |
| Adjusted EBITDA loss, non-GAAP | $40.3 million | $87.9 million |
- Nearly all revenue is capitated: 98% in Q3 and 99% for the nine-month period. Q3 medical expenses were $254.8 million, about 103% of revenue; the operating margin was approximately negative 24%.
- Cash and restricted cash totaled $35.4 million at September 30, including $34.4 million unrestricted, down from $140.8 million total cash at year-end 2021. Current assets were $124.2 million versus current liabilities of $227.1 million.
- Debt principal was $80.0 million: $65.0 million under a term loan and a $15.0 million unsecured note. The term loan bears 12% interest, with the company electing to pay 8% in cash and add 4% to principal as PIK interest. Principal maturities are in 2025 and 2026, respectively.
- Claims payable was $134.7 million and the premium deficiency reserve was $27.7 million at quarter-end.
Changes versus the prior comparable period
- Q3 revenue increased 59% from $156.2 million; nine-month revenue increased 75% from $452.1 million. Management attributed growth mainly to membership expansion, more health-plan contracts, and higher capitation rates.
- At-risk Medicare Advantage membership rose 67%, from approximately 60,600 at September 30, 2021 to 101,000 at September 30, 2022. P3 reported 20 health-plan agreements across five states, compared with 17 across four states at year-end 2021.
- Q3 net loss increased from $32.1 million to $65.3 million, reflecting higher medical, corporate and administrative, and amortization costs. Nine-month net loss includes an $851.5 million goodwill impairment recorded in Q2; without that item, the reported year-over-year loss comparison would be materially different.
- Cash used in operations rose from $39.8 million to $94.1 million for the nine months. Cash declined by $105.5 million during the 2022 period.
- Comparisons require caution: the 2021 figures are restated predecessor results, while 2022 is successor accounting following the December 2021 business combination; the filing says the periods are on different accounting bases.
Outlook, risks, contingencies, and unusual items
- Going concern: Management says available cash is not sufficient to fund operating and capital needs for at least the next 12 months and that substantial doubt exists about the company’s ability to continue as a going concern. It expects continued operating losses and negative cash flows and is exploring additional financing; availability and terms are uncertain. The financial statements include no adjustments for the outcome of this uncertainty.
- Goodwill impairment: The $851.5 million Q2 charge followed a sustained share-price decline, weaker adjusted EBITDA, and higher expected medical costs in forecasts. Goodwill was $463.5 million at September 30; management said it would continue monitoring impairment assumptions.
- Controls: Disclosure controls were not effective at quarter-end because of material weaknesses involving accounting resources and oversight, IT controls, claims estimates, complex transactions, and several significant accounting areas. Remediation is underway but not complete.
- Debt and liquidity risk: The term loan includes a $5.0 million minimum-liquidity covenant and escalating annual revenue covenants. Lenders waived a prior reporting/going-concern-related covenant issue; the company reported compliance with other covenants at September 30, 2022.
- Legal and other contingencies: The Hudson litigation over the business combination continued; certain contract and bad-faith claims were allowed to proceed in court opinions issued after quarter-end. A health-plan contract discrepancy could result in an approximately $10.6 million payment. Management says ordinary-course proceedings are not expected to have a material adverse effect.
- COVID-19-related direct claims costs were estimated at $93.3 million from March 2020 through September 2022. Management reported no material revenue impact through the period but noted future effects remain uncertain.
- No specific financial guidance was provided. Management expects to invest in growth and acknowledges possible need to slow or scale back growth if additional capital is unavailable.
Important facts for investors to verify
- Whether P3 can secure sufficient financing to address the stated 12-month liquidity shortfall and going-concern uncertainty.
- Cash burn, member-level medical costs, claims reserves, and the ability to manage medical expense relative to capitation revenue.
- Progress on remediation of material weaknesses and the reliability of future financial reporting.
- Debt covenant compliance, interest accruals, and the term loan’s PIK balance and maturity obligations.
- Assumptions underlying the goodwill valuation and whether further impairment indicators emerge.
- Outcomes and potential financial exposure from the Hudson litigation and the health-plan contract dispute.